Press Release

Apexigen Selected to Present at Cavendish Global Health Impact Forum

Company to highlight its lead immuno-oncology program and versatile antibody discovery platform to leading family offices and foundations seeking high-impact investments

SAN CARLOS, Calif., May 6, 2015 — Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today it has been selected as an Innovation Partner to present at the Cavendish Global Health Impact Forum taking place May 10th to May 14th in La Jolla, California. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences and is being co-hosted by leading research institutions including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute and The Sanford-Burnham Medical Research Institute.

Apexigen’s President and CEO, Xiaodong Yang, M.D., Ph.D., joins distinguished speakers, academic and clinical thought leaders, health-policy experts and select healthcare and life science companies advancing breakthrough research and clinical programs with the potential to transform disease prevention, diagnosis and treatment. In his presentation, entitled “Apexigen: Realizing the Promise of Immuno-oncology and Transforming Cancer Therapy,” Dr. Yang will describe the Company’s pipeline of clinical-stage and preclinical candidates being developed in-house and through pharmaceutical collaborations, its proprietary antibody technology platform, and the potential to discover new therapeutics that address even the most challenging disease targets. Dr. Yang’s presentation is scheduled for May 11th at 2:10 pm.

“We are developing new cancer therapeutics based on Apexigen’s versatile technology platform, which enables the creation of high-quality antibody drug candidates with high affinity, specificity and stability for a wide variety of difficult-to-treat diseases. Our lead immuno-oncology program APX005M, a monoclonal antibody targeting CD40, has shown best-in-class potential in preclinical evaluation, when combined with checkpoint inhibitors, to treat a wide variety of cancers,” said Dr. Yang. “We are honored to be a part of this unique forum and look forward to highlighting the promise of Apexigen as we advance APX005M into clinical development.”

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, “The theme of our La Jolla, California Forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality Apexigen’s research and scientific insights in oncology and other serious diseases positions the company to make a major contribution to the field.”

About Apexigen

Apexigen, Inc. is a privately held biopharmaceutical company discovering and developing innovative antibody therapeutics for the treatment of life-threatening and difficult-to-treat diseases. Using its proprietary antibody technology platform, Apexigen has discovered a pipeline of product candidates, which are currently at varying stages of development. The lead product candidate, APX005M, is a novel immuno-oncology antibody that stimulates and enhances an immune response against cancer. Apexigen is developing other product candidates in partnership with four leading biopharmaceutical companies in China. In addition, Apexigen has formed strategic partnerships with multi-national pharmaceutical companies, including Janssen Biotech, Alcon Laboratories and Toray Industries to discover first-in-class antibody lead candidates for the partners’ programs.

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

Contacts

Apexigen, Inc.
Mark Nevins
Vice President, Business Development
+1 650-931-6236, ext. 502
info@apexigen.com

For Media Inquiries
Karen L. Bergman
BCC Partners
+1 650-575-1509
kbergman@bccpartners.com

Cavendish Global
Alex Charlton
President, Cavendish Global
+1 917-576-1435
alex.charlton@cavendishglobal.com